Judge dismisses Gilead whistleblower suit; Sanofi Canada yanks Allerject lots on needle problems;

@FiercePharma: San Diego's BioAtla gets $30M from mystery Chinese investor in latest round. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: What's in a name? For newly transformed Allergan, branded sales. Article | Follow @CarlyHFierce

> Gilead Sciences ($GILD) persuaded a federal judge to toss out a whistleblower lawsuit accusing it of selling its HIV-fighting drugs without getting FDA approval to switch manufacturers. Report

> Sanofi's ($SNY) Canada unit pulled two lots of Allerject auto-injectors because of potentially defective needles. Report

> Pfizer ($PFE) Canada rolled out a copay discount plan designed to persuade patients to keep using its brand-name meds after generics have hit the market. Report

> Planning to expand its philanthropic efforts, AbbVie ($ABBV) created a new position focused on those efforts and tapped a government affairs manager, Melissa Walsh, to fill it. Report

> The FDA's new policies to limit antibiotic use in livestock animals are a step in the right direction, but don't go far enough, some experts say. Report

Medical Device News

@FierceMedDev: ICYMI: Sequenom slapped down in prenatal testing patent battle with Ariosa. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Indian feds stake out plan to become a global hub of device manufacturing and innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: Researchers @TAMHSC are developing a test that could diagnose TB in 10 minutes. More from the WSJ | Follow @EmilyWFierce

> Philips, Siemens score big hospital bundling contracts, highlighting demand for value-based healthcare. Article

> Merck KGaA partner Genea gets CE mark for a pair of IVF technologies. Report

Biotech News

@FierceBiotech: Pulmatrix hits Wall Street with $10M and a Mylan deal. Report | Follow @FierceBiotech

@JohnCFierce: Trending: Why did Briggs Morrison give up R&D leader role at $AZN to run a biotech? Story | Follow @JohnCFierce

@DamianFierce: I just watched Boyz II Men introduce BIO CEO Jim Greenwood and I'm dead now. | Follow @DamianFierce

> Upstart Kezar wrangles $23M to pick up where Onyx left off. Article

> Bayer bets on Johns Hopkins for eye disease R&D. Report

> Avalanche tanks after its gene therapy posts a modest effect on AMD. Story

Pharma Manufacturing News

> Health Canada bans Hospira drugs coming from Italy plant. News

> Pam Cheng leaves Merck for top manufacturing job at AstraZeneca. Item

> India's Polydrug Labs criticized for contaminated APIs. More

> Pfizer supplements its China production with $90M plant. Story

> FDA upgrades standing of Jubilant U.S. sterile plant cited in 2013. Article

Drug Delivery News

> WHO adds postpartum contraceptive ring to 2015 essential meds list. Article

> Study finds Novo's tablet for vaginal atrophy increases compliance compared to creams. Item

> ADA: Nasal powder and artificial pancreas with glucagon both show potential. Story

> Biotie nets $56M+ in IPO, fellow Parkinson's player Cynapsus up next, followed by Intec Pharma. More

> Oculus receives FDA clearance for novel, spray-based wound care formulation. Report

Pharma Asia News

> Japan's PAFSC backs Lilly's dulaglutide, among others, in latest round. News

> NanoCarrier aims for PhI study on neck cancer in Japan for NC-6004. Report

> Video prescriptions, advice, on the cards for hard-pressed patients in Japan. More

> Deputy at China agency that probed GSK arrested for corruption, report says. Story

> China plans to ensure private hospitals get subsidies, finance. Article

And Finally... St. Jude Medical ($STJ) rolled out a pain-relief device controlled by iPod and iPad. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.